NEW YORK, March 18, 2023 /PRNewswire/ — Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the therapy of palmar hyperhidrosis working with its patented microchannel technologies™. DTX-024 is a extremely purified and clinically tested injectable neuromodulator derived from neurotoxins created by Clostridium botulinum.
Aquavit Logo (PRNewsfoto/Aquavit Pharmaceuticals, Inc.)
Alongside Aquavit’s biosimilar system for its botulinum toxin, this will be the initially in the planet, indicated for palmar hyperhidrosis, authorized by FDA.
Aquavit has been investing in proprietary delivery technologies and associated intellectual house for botulinum toxin. This is a strategic move that puts them ahead of the curve in the rapidly-increasing multi-billion-dollar botulinum toxin marketplace.
To successfully execute the tactic, Aquavit has lately bolstered its executive group with seasoned veterans from the sector and the academia.
Dr. David Crean, PhD, MBA has been named Chief Economic Officer of Aquavit Holdings. He has get- and sell-side knowledge in mergers & acquisitions (M&A), partnering and investments inside the life sciences and healthcare sectors functioning inside strategic biopharmaceutical businesses, private equity, investment banking and venture capital. He commenced his profession inside biopharmaceutical businesses a lot more than 30 years ago, most notably at Allergan, an Abbvie Organization, exactly where he lead deal execution for each technologies, solution, and organization acquisitions and divestitures across a broad variety of therapeutic locations and small business units such as injectable and topical health-related aesthetics, dermatology, neurology, and ophthalmology. He serves on various boards such as each public and private businesses and has been awarded a lot of recognitions such as San Diego’s 500 Most Influential folks for the previous 4 years (2019 -2022), 2020 Major Believed Leaders by Axial, M&A Advisor of the Year in 2019, and the 2018 Healthcare Hero Award.
Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Investment Banking Representative of BA Securities LLC, Member FINRA SIPC.
Story continues
Dr. Churlsu Kwon, MD. PhD. MPH., has been named Chief Healthcare Officer. He is a educated neurosurgeon and neuroscientist who brings a wealth of knowledge and understanding to scientific developments, drug improvement and approval, and new drug discovery. He holds his degrees from University of Oxford and Harvard Healthcare College and at the moment holds an academic position at Columbia Healthcare College.
With Aquavit’s established track record of creating and launching worldwide brands, such as AQUAGOLD®, the organization has demonstrated their capability to effectively bring revolutionary solutions to marketplace. With their deep understanding of botulinum toxin and substantial network of physicians, Aquavit is effectively-positioned to make a considerable effect in the sector.
“The neurotoxin marketplace is expanding quickly, with growing demand for revolutionary solutions and customized therapy plans. There is at the moment no FDA approval for palmar hyperhidrosis and by way of our novel route of administration we will be capable to supply new options to meet the evolving requires of sufferers in pathologies that are really debilitating. The provision of access for this population is a step in the suitable path towards enhancing their overall health and effectively-becoming. ” Churl-Su Kwon, CMO Aquavit.
About Aquavit
Aquavit is an revolutionary healthcare organization that delivers a extensive variety of proprietary pharmaceutical, biotech and health-related device technologies. Aquavit focuses on customized medicine to enhance patients’ overall health, maximize the efficiency of our health-related neighborhood, and help the pharmacoeconomics of payers.
Cision
View original content material to download multimedia:https://www.prnewswire.com/news-releases/aquavit-files-more-ind-for-dtx-024-a-new-botulinum-toxin-with-microchannel-technologies-for-palmar-hyperhidrosis-301775589.html
Supply Aquavit Holdings
